Exhibit 5.1

Fennemore Craig, P.C.
300 E. Second Street

Suite 1510

Reno, Nevada 89501

(775) 788-2200

October 2, 2015

Relmada Therapeutics, Inc.

757 3rd Avenue, Suite 2018

New York, New York 10017

Ladies and Gentlemen:

You have requested our opinion with respect to certain matters in connection with the registration under the Securities Act of 1933, as amended (the “Act”), by Relmada Therapeutics, Inc., a Nevada corporation (the “Company”), by means of a registration statement on Form S-8 (as it may be amended and supplemented, the “Registration Statement”) filed with the Securities and Exchange Commission (the “Commission”) relating to (i) the registration and resale of 996,818 shares (the “Current Shares”) of common stock, par value $0.001 per share (the “Common Stock”), consisting of restricted shares of the Company’s Common Stock previously issued pursuant to the Relmada Therapeutics, Inc. 2014 Stock Option and Equity Incentive Plan, as amended (the “Plan”) as well as shares of the Company’s Common Stock underlying outstanding options previously granted under the Plan, (ii) options (“Options”) that may be granted under the Plan to purchase up to an aggregate of 614,952 shares of the Company’s Common Stock, and (iii) up to an aggregate of 614,952 shares of Common Stock of the Company which may underlie options to be granted under the Plan, or which may be stock or other awards which are subject to future grants under the Plan (the “Future Shares”).

In connection with this opinion, we have examined and relied upon the Registration Statement, the Company’s Articles of Incorporation and Bylaws, each as amended and currently in effect, and the originals or copies certified to our satisfaction of such other documents, records, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have examined originals or copies of such other corporate records, certificates of corporate officers and public officials and other agreements and documents as we have deemed necessary or advisable for purposes of this opinion letter. We have relied upon the certificates of all public officials and corporate officers with respect to the accuracy of all factual matters contained therein.

Fennemore Craig

Relmada Therapeutics, Inc.

October 2, 2015

Page 2

On the basis of the foregoing, and in reliance thereon, we are of the opinion that:

With respect to any Current Shares or Future Shares that are issued after the date of this opinion letter, we have assumed that at the time of issuance, the Corporation has sufficient authorized, but unissued shares available to allow for such issuance.

The opinions expressed above are limited to the laws of the State of Nevada, including reported judicial decisions. This Opinion Letter is intended solely for use in connection with the registration and offering of the Common Stock as described in the Registration Statement and resales of the Common Stock, and it may not be reproduced or filed publicly, without the written consent of this firm; provided, however, we hereby consent to the filing of this Opinion Letter as an exhibit to the Registration Statement and to the use of our name under the heading “Legal Matters” contained in the Prospectus included in the Registration Statement. In giving this consent, we do not hereby admit that we are in a category of persons whose consent is required pursuant to Section 7 of the Securities Act of 1933 or the rules and regulations of the Securities and Exchange Commission promulgated thereunder.